4.5 Review

Meta-analytic review of neurocognition in bipolar II disorder

期刊

ACTA PSYCHIATRICA SCANDINAVICA
卷 123, 期 3, 页码 165-174

出版社

WILEY
DOI: 10.1111/j.1600-0447.2010.01638.x

关键词

bipolar disorder; type II; cognition; neuropsychology; meta-analysis

向作者/读者索取更多资源

Objective: The clinical distinction between bipolar II disorder (BD II) and bipolar I disorder (BD I) is not clear-cut. Cognitive functioning offers the potential to explore objective markers to help delineate this boundary. To examine this issue, we conducted a quantitative review of the cognitive profile of clinically stable patients with BD II in comparison with both patients with BD I and healthy controls. Method: Meta-analytical methods were used to compare cognitive functioning of BD II disorder with both BD I disorder and healthy controls. Results: Individuals with BD II were less impaired than those with BD I on verbal memory. There were also small but significant difference in visual memory and semantic fluency. There were no significant differences in global cognition or in other cognitive domains. Patients with BD II performed poorer than controls in all cognitive domains. Conclusion: Our findings suggest that with the exception of memory and semantic fluency, cognitive impairment in BD II is as severe as in BD I. Further studies are needed to investigate whether more severe deficits in BD I are related to neurotoxic effects of severe manic episodes on medial temporal structures or neurobiological differences from the onset of the illness.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Neurosciences

Interactive relationships of Type 2 diabetes and bipolar disorder with cognition: evidence of putative premature cognitive ageing in the UK Biobank Cohort

Elysha Ringin, David W. Dunstan, Roger S. McIntyre, Michael Berk, Neville Owen, Susan L. Rossell, Tamsyn E. Van Rheenen

Summary: Type 2 diabetes is more prevalent in bipolar disorder and is linked to cognitive deficits. This study explored the interaction between type 2 diabetes, bipolar disorder, and cognition, as well as the effect of age on cognitive performance in bipolar disorder with type 2 diabetes. The results showed that type 2 diabetes was associated with a negative impact on visuospatial memory in bipolar disorder. Processing speed and prospective memory were also negatively affected by type 2 diabetes, regardless of bipolar disorder diagnosis. Cognitive deficits were evident in bipolar disorder patients with type 2 diabetes compared to those without, and their cognitive performance remained stable or improved as they aged. In contrast, bipolar disorder patients without type 2 diabetes showed worse cognitive performance as they aged, but the age-related trajectory was similar to the psychiatrically healthy comparison group. The study suggests that comorbid type 2 diabetes may contribute to cognitive dysfunction in bipolar disorder, and bipolar disorder patients with type 2 diabetes may experience premature deterioration of cognitive functioning.

NEUROPSYCHOPHARMACOLOGY (2023)

Article Psychiatry

Predictors of suicidal ideation severity among treatment-seeking young people with major depressive disorder: The role of state and trait anxiety

Carl Moller, Paul B. Badcock, Sarah E. Hetrick, Simon Rice, Michael Berk, Katrina Witt, Andrew M. Chanen, Olivia M. Dean, Caroline Gao, Sue M. Cotton, Christopher G. Davey

Summary: This study aimed to identify the specific factors that contribute to changes in suicidal ideation over time among young people with depression. The results showed that the severity of depression and anxiety symptoms, as well as personality traits, independently predicted higher suicidal ideation.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Clinical Neurology

Paper Charts A Continued Barrier to Psychiatric Care in the Midst of a Broken and Fragmented Mental Health System

Emma D. Frost, Jack Donlon, Aimin Mitwally, Gretchen Magnani, Shay Tomlin, Michael Berk, Maju Mathew Koola

Summary: The use of electronic medical records has increased significantly, but psychiatry lags behind. Financial burden, lack of technological support, stigma, and privacy concerns contribute to the low adoption rate in mental health field. The use of paper charts in psychiatric care can disrupt continuity and emergency care. This article addresses the challenges and benefits of implementing electronic medical records in psychiatry.

JOURNAL OF NERVOUS AND MENTAL DISEASE (2023)

Article Engineering, Biomedical

Development of an integrated microperfusion-EEG electrode for unbiased multimodal sampling of brain interstitial fluid and concurrent neural activity

Luke A. Stangler, Evan N. Nicolai, Filip Mivalt, Su-Youne Chang, Inyong Kim, Abbas Z. Kouzani, Kevin Bennet, Michael Berk, Susheil Uthamaraj, Terry C. Burns, Gregory A. Worrell, Charles L. Howe

Summary: An off-the-shelf device was modified to collect brain interstitial fluid (ISF) from macroelectrodes, allowing unbiased sampling at the site of stimulation or seizure activity. The modified device was tested in a pig brain, and proteomic analysis revealed a unique inflammatory signature induced by electrical stimulation.

JOURNAL OF NEURAL ENGINEERING (2023)

Article Neurosciences

High frequency deep brain stimulation can mitigate the acute effects of cocaine administration on tonic dopamine levels in the rat nucleus accumbens

Jason Yuen, Abhinav Goyal, Aaron E. E. Rusheen, Abbas Z. Z. Kouzani, Michael Berk, Jee Hyun Kim, Susannah J. J. Tye, Charles D. D. Blaha, Kevin E. E. Bennet, Kendall H. Lee, Hojin Shin, Yoonbae Oh

Summary: Cocaine increases dopamine levels in the nucleus accumbens (NAc) by stimulating the ventral tegmental area (VTA). This study found that high frequency stimulation (HFS) of the VTA or NAcc can modulate the effects of cocaine on dopamine levels. HFS of the VTA decreased dopamine levels, while HFS of the NAcc initially decreased levels and then returned to baseline. HFS following cocaine administration prevented the increase in dopamine levels. This suggests the potential of deep brain stimulation (DBS) in the treatment of substance use disorders (SUDs) by abolishing cocaine-induced dopamine release.

FRONTIERS IN NEUROSCIENCE (2023)

Article Medicine, Research & Experimental

Safety and feasibility of faecal microbiota transplant for major depressive disorder: study protocol for a pilot randomised controlled trial

Jessica E. E. Green, Amelia J. J. McGuinness, Michael Berk, David Castle, Eugene Athan, Christopher Hair, Philip Strandwitz, Amy Loughman, Andrew A. A. Nierenberg, John F. F. Cryan, Mohammadreza Mohebbi, Felice Jacka

Summary: This study aims to evaluate the feasibility and safety of Faecal Microbiota Transplants (FMT) as a treatment for moderate-to-severe major depressive disorder (MDD) and investigate its impact on the gut microbiota. A randomized controlled trial will be conducted, with one group receiving FMT treatment and another group receiving a placebo. The results of this study will help determine if FMT can be a new treatment for depression.

PILOT AND FEASIBILITY STUDIES (2023)

Article Medicine, Research & Experimental

Is paternal immune activation just as important as maternal immune activation? Time to rethink the bi-parental immune priming of neurodevelopmental model of schizophrenia

Monojit Debnath, Michael Berk

Summary: The neurodevelopmental origin of schizophrenia is influenced by parental exposure to environmental adversities and alterations in immune and stress-regulatory pathways. Maternal immune activation, induced by maternal infections, has been identified as a key pathway in the development of schizophrenia. However, the role of paternal immune activation and the underlying mechanisms are still not well understood. This article highlights the potential mechanisms linking paternal immune activation and the risk of schizophrenia and proposes the possibility of bi-parental immune priming as a risk mechanism. Understanding these mechanisms will have important implications for the etiology and prevention of schizophrenia.

MEDICAL HYPOTHESES (2023)

Article Biochemistry & Molecular Biology

Psychosis brain subtypes validated in first-episode cohorts and related to illness remission: results from the PHENOM consortium

Dominic B. Dwyer, Ganesh B. Chand, Alessandro Pigoni, Adyasha Khuntia, Junhao Wen, Mathilde Antoniades, Gyujoon Hwang, Guray Erus, Jimit Doshi, Dhivya Srinivasan, Erdem Varol, Rene S. Kahn, Hugo G. Schnack, Eva Meisenzahl, Stephen J. Wood, Chuanjun Zhuo, Aristeidis Sotiras, Russell T. Shinohara, Haochang Shou, Yong Fan, Maristela Schaulfelberger, Pedro Rosa, Paris A. Lalousis, Rachel Upthegrove, Antonia N. Kaczkurkin, Tyler M. Moore, Barnaby Nelson, Raquel E. Gur, Ruben C. Gur, Marylyn D. Ritchie, Theodore D. Satterthwaite, Robin M. Murray, Marta Di Forti, Simone Ciufolini, Marcus V. Zanetti, Daniel H. Wolf, Christos Pantelis, Benedicto Crespo-Facorro, Geraldo F. Busatto, Christos Davatzikos, Nikolaos Koutsouleris, Paola Dazzan

Summary: Using machine learning, researchers found that schizophrenia can be decomposed into two volumetric subgroups with distinct neuroanatomical characteristics: a 'lower brain volume' subgroup and a 'higher striatal volume' subgroup. These subgroups were already present at the first episode of psychosis and were associated with different clinical presentations and remission outcomes. The findings suggest that these subgroups may be important in understanding the underlying mechanisms of schizophrenia and could be targeted in future treatment trials.

MOLECULAR PSYCHIATRY (2023)

Article Biochemistry & Molecular Biology

Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis

Kate Merritt, Robert McCutcheon, Andre Aleman, Sarah Ashley, Katherine Beck, Wolfgang Block, Oswald J. N. Bloemen, Faith Borgan, Christiana Boules, Juan R. Bustillo, Aristides Capizzano, Jennifer Q. Coughlin, Anthony David, Camilo de la Fuente-Sandoval, Arsime Demjaha, Kara Dempster, Kim Do, Fei E. Du, Peter Falkai, Beata Galinska-Skok, Juergen Gallinat, Charles Gasparovic, Cedric E. Ginestet, Naoki Goto, Ariel Graff-Guerrero, Beng-Choon Ho, Oliver Howes, Sameer Jauhar, Peter Jeon, Tadafumi Kato, Charles A. Kaufmann, Lawrence S. Kegeles, Matcheri S. Keshavan, Sang-Young Kim, Bridget King, Hiroshi Kunugi, J. Lauriello, Pablo Leon-Ortiz, Edith Liemburg, Meghan Mcilwain, Gemma Modinos, Elias Mouchlianitis, Jun Nakamura, Igor Nenadic, Dost Ongur, Miho Ota, Lena E. Palaniyappan, Christos Pantelis, Tulsi F. Patel, Eric Plitman, Sotirios R. Posporelis, Scot Purdon, Juergen R. Reichenbach, Perry C. Renshaw, Francisco Reyes-Madrigal, Bruce A. Russell, Akira Sawa, Martin Schaefer, Dikoma C. Shungu, Stefan Smesny, Jeffrey Stanley, James G. Stone, Agata Szulc, Reggie Taylor, Katharine N. Thakkar, Jean J. Theberge, Philip Tibbo, Therese van Amelsvoort, Jerzy Walecki, Peter Williamson, Stephen Wood, Lijing Xin, Hidenori Yamasue, Philip K. McGuire, Alice Egerton

Summary: This study conducted meta-analyses and found that patients with schizophrenia have greater variability in glutamate metabolites compared to controls in various brain regions, and age and symptoms also influence individual variability.

MOLECULAR PSYCHIATRY (2023)

Article Psychiatry

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

Colleen Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B. Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew A. Somogyi, Kyle Lapidus, Elizabeth Stratton, Kirsten Gainsford, Deepak Garg, Nicollette L. R. Thornton, Celia Fourrier, Karyn Richardson, Demi Rozakis, Anish Scaria, Cathrine Mihalopoulos, Mary Lou Chatterton, William M. Mcdonald, Philip Boyce, Paul E. Holtzheimer, F. Andrew Kozel, Patricio Riva-Posse, Anthony Rodgers

Summary: This study is a phase 3 trial on the efficacy and safety of subcutaneous racemic ketamine in the treatment of treatment-resistant depression (TRD). The results showed that subcutaneous racemic ketamine was effective and safe over a 4-week treatment period. The dosing and route of administration were considered practical and feasible.

BRITISH JOURNAL OF PSYCHIATRY (2023)

Editorial Material Medicine, General & Internal

Mental health of young Australians: dealing with a public health crisis

Patrick D. McGorry, David Coghill, Michael Berk

MEDICAL JOURNAL OF AUSTRALIA (2023)

Editorial Material Nutrition & Dietetics

Nutrition and brain: bidirectional link in neuropsychiatry disorders

Lais Bhering Martins, Michael Berk, Adaliene Versiani Matos Ferreira, Antonio Lucio Teixeira

FRONTIERS IN NUTRITION (2023)

Meeting Abstract Geriatrics & Gerontology

THE NEGLECTED ASSOCIATION BETWEEN SCHIZOPHRENIA AND BONE FRAGILITY: A SYSTEMATIC REVIEW AND META-ANALYSES

B. Azimi Manavi, K. B. Corney, M. Mobebbi, S. E. Shae, A. L. Stuart, J. A. Pasco, J. M. Hodge, M. Berk, L. J. Williams

AGING CLINICAL AND EXPERIMENTAL RESEARCH (2023)

Article Neurosciences

Regional, circuit and network heterogeneity of brain abnormalities in psychiatric disorders

Ashlea Segal, Linden Parkes, Kevin Aquino, Seyed Mostafa Kia, Thomas Wolfers, Barbara Franke, Martine Hoogman, Christian F. Beckmann, Lars T. Westlye, Ole A. Andreassen, Andrew Zalesky, Ben J. Harrison, Christopher G. Davey, Carles Soriano-Mas, Narcis Cardoner, Jeggan Tiego, Murat Yucel, Leah Braganza, Chao Suo, Michael Berk, Sue Cotton, Mark A. Bellgrove, Andre F. Marquand, Alex Fornito

Summary: Traditional case-control research often ignores the substantial individual heterogeneity among people with mental illness. This study provides a comprehensive, multiscale characterization of gray matter volume differences in six mental disorders. The results show that individual deviations in regional gray matter volume are highly heterogeneous, but some of these deviations are embedded within common functional circuits and networks.

NATURE NEUROSCIENCE (2023)

Article Clinical Neurology

Equal remission rates and reduced length of hospital stay with twice-daily repetitive transcranial magnetic stimulation (rTMS) for major depression - A large naturalistic retrospective cohort association study

R. Barnes, D. Skvarc, P. B. Fitzgerald, M. Berk, O. M. Dean, S. Dodd, T. Schriemer, A. B. Singh

Summary: This study compares the effects of once and twice daily rTMS treatment for depression, and finds similar remission rates between the two groups. However, twice daily treatment requires a shorter length of hospital stay, which has significant cost implications.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2023)

暂无数据